“By dividing and conquering…we’re seeing responses in multiple different subtypes of sarcoma…and moving toward more of an individualized therapy that we try to design for every patient, where we take ...

Fiscal 2026 Quarterly Outlook -- Net sales projected at $32 million to $35 million, operating expenses expected to increase slightly from the first quarter, and net loss per diluted share guided to a ...